Actively Recruiting
Reduction of Adverse Drug Events and Readmissions
Led by ClinLogic LLC · Updated on 2024-02-07
280000
Participants Needed
1
Research Sites
402 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
CONDITIONS
Official Title
Reduction of Adverse Drug Events and Readmissions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients 25 years of age or older who can provide written informed consent
- Patient underwent pharmacogenomic testing for relevant alleles within the prior 120 days
- Patient is receiving at least one medication known to be associated with genetic variation, including over-the-counter medications
- Patient has a history of at least one treatment-related adverse drug event or inadequate drug efficacy in the 24 months before the pharmacogenomic test assessment
You will not qualify if you...
- Patient is currently hospitalized
- Patient's medical and medication history is unavailable for the 120 days before the pharmacogenomic test assessment
- Patient cannot provide an accurate medical history due to mental incapacity
- Patient has had prior pharmacogenomic testing specific to the target drug(s) other than the test related to this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD@Home
York, Pennsylvania, United States, 17402
Actively Recruiting
Research Team
D
Diana Messir
CONTACT
D
Diana M Messir
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here